Therapeutic | Gemtuzumab |
Target | CD33 |
Heavy Chain | EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS |
Light Chain | DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb ADC |
Isotype | G4 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | NFD |
Recorded Developmental Technology | na |
INN Year Proposed | 2016 |
INN Year Recommended | 2017 |
Companies Involved | UCB, Celgene Corporation, Pfizer, University of California San Diego |
Conditions Approved | Acute myeloid leukaemia |
Conditions Active | na |
Conditions Discontinued | na |
Notes |